Q2 2026 AstraZeneca PLC Earnings Call Transcript
Key Points
- AstraZeneca PLC (AZN) reported a 6% increase in total revenue for the first half of 2026, with product revenue also growing by 6%.
- The company achieved strong growth in core EPS, increasing by 11%, demonstrating robust financial performance.
- AstraZeneca PLC (AZN) announced positive results from six key Phase III programs, including three new molecular entities, and secured 30 major market approvals.
- The oncology and rare disease segments delivered strong double-digit growth, with notable revenue increases in the US and Europe.
- AstraZeneca PLC (AZN) continues to invest in its pipeline and commercial capabilities, with a focus on innovative medicines and long-term growth opportunities.
- Growth in China was impacted by continued effects from volume-based procurement, affecting overall revenue growth.
- The results of the cardio-TTR transform trial were disappointing, highlighting the inherent risks in transformative science.
- AstraZeneca PLC (AZN) faces challenges from loss of exclusivity for key products like Fasiga and Brilinta, impacting revenue.
- The company anticipates a lower gross margin in the second half of the year due to seasonal demand patterns for lower margin medicines.
- Net debt increased by around $3.5 billion in the first half, primarily due to dividend payments and deal-related expenses.
Good morning to those joining from the UK and the US. Good afternoon to those in Central Europe and good evening to those listening in Asia. Welcome to AstraZeneca's half-one and Q2 2026 webinar for investors and analysts.
Before I hand over to AstraZeneca, I'd like to read the Safe Harbour Statement. The company intends to utilize the Safe Harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Participants on this call may make forward-looking statements with respect to the operations and financial performance of AstraZeneca.
Although we believe our expectations are based on reasonable assumptions, by their very nature, forward-looking statements involve risks and uncertainties. And may be influenced by factors that could cause actual results to differ materially from those expressed or implied by these forward-looking statements. Any forward-looking statements made on this call reflect the knowledge and information available at the time of this call.
The company undertakes no obligation to update forward-looking statements. Please also
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
